Effect of a single inhalation of laninamivir octanoate in children with influenza

Pediatrics

Volumn 129, Issue 6, 2012, Pages

  Katsumi, Yoshiki ^a   Otabe, Osamu ^a   Matsui, Fumihiro ^a   Kidowaki, Satoshi ^a   Mibayashi, Akiko ^a   Tsuma, Yusuke ^a   Ito, Hisato ^a  

^a NANTAN GENERAL HOSPITAL   (Japan)

Author keywords

Child; Influenza; Laninamivir; Neuraminidase; Zanamivir

Indexed keywords

LANINAMIVIR OCTANOATE; ZANAMIVIR;

ABNORMAL BEHAVIOR; ADOLESCENT; ARTICLE; ASTHMA; CHILD; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA B; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADMINISTRATION, INHALATION; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; INFLUENZA, HUMAN; MALE; NEURAMINIDASE; QUESTIONNAIRES; TREATMENT OUTCOME; ZANAMIVIR;

EID: 84861883976     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-2054     Document Type: Article

References (14)

1. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009; 302(17):1880-1887
2. Jain S, Kamimoto L, Bramley AM, et al; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20):1935-1944
3. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000;19 (5):410-417 (Pubitemid 30307990)
4. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009;53(1):186-192
5. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460 (7258):1021-1025
6. Kiso M, Kubo S, Ozawa M, et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog. 2010;6(2):e1000786
7. Koyama K, Takahashi M, Oitate M, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother. 2009;53(11):4845-4851
8. Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother. 2010;54(3):1256-1264
9. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54(6):2575-2582
10. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51(10): 1167-1175
11. Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother. 2011;17(5):595-601
12. The Ministry of Health. Labor and welfare in Japan. Available at: http://idsc.nih.go.jp/ disease/influenza/search/2011-12/pdf-b.pdf. Accessed March 20, 2012
13. Gubareva LV, Trujillo AA, Okomo-Adhiambo M, et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther. 2010;15(8):1151-1159
14. Infectious Agents Surveillance Report in Japan. Available at: http://idsc.nih.go.jp/iasr/ virus/Pdf/Inf00-09s.pdf. Accessed March 20, 2012